Sun Pharma, Ranbaxy based on macro, company-specific triggers: Surjit Pal

Focusing on the completely different trajectory, both Sun Pharma and Ranbaxy stocks are based on macro and company-specific triggers, says pharma analyst Surjit Pal. Mr Pal says that Sun's planned Meda buyout is going to strain the balance sheet but it may project the company higher up in the earnings landscape in the long run. Ranbaxy's problems, however, are compounding with each passing day and lack of clarity on manufacturing practices does not augur well for the company, he says.